Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10568MR)

This product GTTS-WQ10568MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10568MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9674MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ1667MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ4512MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ15758MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ9623MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7953MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ3240MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ13089MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW